Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
EXHIBIT
99.1
Cellular Biomedicine Group Announces Results of 2018 Annual Meeting
of Stockholders
SHANGHAI, China and CUPERTINO, Calif., April 30, 2018 (GLOBE
NEWSWIRE) -- Cellular Biomedicine
Group Inc. (NASDAQ:
CBMG) (“CBMG” or the “Company”), a
clinical-stage biopharmaceutical firm engaged in the development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, today announced the voting results of its 2018
Annual Meeting of Stockholders, held on April 27, 2018
in Cupertino, California. Approximately 79% of the
Company’s outstanding shares were represented at the
2018 Annual Meeting.
The following business items were approved by a strong
majority at the Annual Meeting:
1.
The
election of three (3) “Class III” directors, each of
whom will be elected for a term of three years, or until the
election and qualification of their successors: Wen Tao (Steve)
Liu, Nadir Patel, and Bosun S. Hau.
2.
Ratification
of the appointment of BDO China Shu Lun Pan Certified Public
Accountants LLP as the Company’s independent registered
public accounting firm for the fiscal year ending December 31,
2018.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc.
(NASDAQ:CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of twelve
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. Our Shanghai
facility includes a ”Joint Laboratory of Cell Therapy”
with GE Healthcare and a “Joint Cell Therapy Technology
Innovation and Application Center” with Thermo Fisher
Scientific, which partnerships focus on improving manufacturing
processes for cell therapies. CBMG currently has ongoing CAR-T
Phase I clinical trials in China; CARD-1 for Diffuse Large B-cell
Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL) and CALL-1 for
adult Acute Lymphoblastic Leukemia (ALL), utilizing CBMG’s
proprietary and optimized CD19 construct, a Phase IIb trial in
China for Rejoin® autologous Human Adipose-derived Mesenchymal
Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis
(KOA) as well as a Phase I trial in China for AlloJoin™
(CBMG’s “Off-the-Shelf” haMPC) for the treatment
of KOA. In Q1 2018 CBMG was added to the Loncar China BioPharma
index. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts and may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include those
regarding our ability to implement our plans, strategies and
objectives for future operations, including our plan to configure
part of our Shanghai facility with GE Healthcare’s
FlexFactory platform, our ability to execute on proposed new
products, services or development thereof, results of our clinical
research and development, regulatory infrastructure governing cell
therapy and cellular biopharmaceuticals, our ability to enter into
agreements with any necessary manufacturing, marketing and/or
distribution partners for purposes of commercialization, our
ability to seek intellectual property rights for our product
candidates, competition in the industry in which we operate,
overall market conditions, any statements or assumptions underlying
any of the foregoing and other risks detailed from time to time in
CBMG’s reports filed with the Securities and Exchange
Commission, quarterly reports on form 10-Q, current reports on form
8-K and annual reports on form 10-K. Forward-looking statements may
be identified by terms such as “may,”
“will,” “expects,” “plans,”
“intends,” “estimates,”
“potential,” or “continue,” or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com